DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election without traverse of Species A in the reply filed on 4/29/2026 is acknowledged. Claims 11-16 were withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Species, there being no allowable generic or linking claim.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 5/6/2025 was filed in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Claim Objections
Claim 10 is objected to because of the following informalities: the claim recites a “specific of between .6 and .7.” It is believed the claim should state a ”specificity.” Appropriate correction or clarification is required.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-5, 17-19 and 21 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Rahman et al. (“Early Detection of Kidney Disease Using ECG Signals Through Machine Learning Based Modelling,” Examiner-cited NPL published in 2019, hereinafter Rahman).
Regarding claims 1-5, 17-19 and 21, Rahman discloses a system and method for analyzing kidney health in an individual (see title). Rahman receives 12-lead ECG data (see page 320). Cardiac data characteristics of an individual such as QRS complex amplitudes, QT interval and RR interval (i.e., heart rate) are input into a machine learning model and the machine learning model outputs an indication of the presence of CKD in a patient if, for example, the individual shows a prolonged QT interval (pages 320-322). The indication of CKD inherently means the individual has at least one of mild CKD, moderate-severe CKD, or ESRD.
Claims 1-4, 10 and 21 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Noshay et al. (US 2022/0093261, hereinafter Noshay).
Regarding claims 1-4, 10 and 21, Rahman Noshay a system and method for analyzing kidney health in an individual (see title). Rahman receives a cardiac data characteristic of an individual such as a history of cardiac ischemia or CHF are input into a machine learning model and the machine learning model outputs an indication of the presence of CKD and the stage of the CKD, including ESRD (par. 0009, 0056, 0063, 0066, Table 1). The model has a sensitivity of between 0.6 and 0.7 (see Table 3).
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 6-9 are rejected under 35 U.S.C. 103 as being unpatentable over Rahman in view of Noshay.
Regarding claims 6-9, Rahman discloses the applicant’s basic invention, as described above. Rahman also discloses that it is important that the model be accurate in the diagnosis, and that the model has an accuracy of 97.6% (see page 321). Rahman is silent as to using area under the curve (AUC) of a receiver operating characteristic (ROC) when training the model. However, Noshay discloses that AUC of a RUC is important to determine the discriminative accuracy of a machine learning model, such that a value above 0.5 ensures that the model is not just guessing, and that a value closer to 1.0 would indicate a more perfect predictive accuracy (see Table 3 and Table 7). Therefore, it would have been obvious to one of ordinary skill in the art before the applicant’s effective filing date to modify Rahman to have an AUC of ROC above 0.5 in predicting CKD stages in order to ensure predictive accuracy. With regards to the AUC specifically being 0.73-0.78, it has been held that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation" (see In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955)). In this case, Noshay shows that an AUC is a results-effective variable whose value indicates predictive accuracy. Therefore, adjusting the AUC as needed to balance the potential consequences of false negative and false positives is not inventive, and if a value between 0.73 and 0.78 produced optimal results, then that would have been obvious to one of ordinary skill in the art before the applicant’s effective filing date.
Claim 20 is rejected under 35 U.S.C. 103 as being unpatentable over Rahman or Noshay in view of Tangri (US 2023/0054069).
Both Rahman and Noshay disclose the use of machine learning models to analyze kidney health. However, both Rahman and Noshay are silent as to the machine learning model specifically being a convolutional neural network. Tangri also discloses a machine learning model to analyze kidney health, and thus is analogous art with Rahman and Noshay (see abstract). Tangri discloses that convolutional neural networks is a known type of machine learning model that can be used for this purpose (par. 0053). Therefore, it would have been obvious to one of ordinary skill in the art before the applicant’s effective filing date to specifically use a convolutional neural network as the machine learning model in Rahman and/or Noshay as Tangri teaches a convolutional neural networks is a known type of machine learning model in the kidney diagnosis art and thus would produce a predictable result that would not affect the overall operation or purpose of Rahman nor Noshay.
Conclusion
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. See attached PTO-892, specifically US 2025/0099000 which also discloses a machine learning model for indicating progression of kidney disease.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eric D Bertram whose telephone number is (571)272-3446. The examiner can normally be reached Monday-Friday 8am-6pm Central Time.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer McDonald can be reached at 571-270-3061. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Eric D. Bertram/Primary Examiner, Art Unit 3796